HC Wainwright & Co. Maintains Buy on Eledon Pharma, Raises Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Vernon Bernardino maintains a Buy rating on Eledon Pharma (NASDAQ:ELDN) and raises the price target from $13 to $16.

May 07, 2024 | 2:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eledon Pharma's price target has been raised from $13 to $16 by HC Wainwright & Co., with a maintained Buy rating.
The increase in price target by a reputable analyst firm like HC Wainwright & Co. typically signals a positive outlook on the stock, suggesting potential upside. This is based on the firm's analysis and confidence in the company's future performance, which can influence investor sentiment and potentially lead to a short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100